Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD Instinct™ accelerators and ROCm™ software to power ...

AMD high-performance compute will enable us to further the development of next-generation antibody therapeutics ... holds to accelerate the future of drug discovery." “We are proud to partner ...

Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy AMD ...

Alloy Therapeutics ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...

AMd (AMD) said via X that it is partnering with drug-discovery company Absci (ABSI). “AMD is proud to announce we are partnering with @abscibio ...

Absci shares are rising after announcing a strategic collaboration with Advanced Micro Devices Inc. The partnership will ...

AMD's technology will also be used to boost Absci's drug discovery workload, including the company's de novo antibody design ...

With this model, researchers may be able to discover antibody drugs capable of targeting a wide range of infectious diseases.

Boehringer Ingelheim has acquired a licence for the development of antibody-based cancer treatments from Oxford ...

Many vaccines work by introducing a protein to the body that resembles part of a virus. Ideally, the immune system will produce long-lasting antibodies recognizing that specific virus, thereby ...